Holandia - niderlandzki - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mae holding b.v. stationsweg 4 5211 tw 's-hertogenbosch - amylmetacresol 0,6 mg/stuk ; dichloorbenzylalcohol 1,2 mg/stuk ; lidocainehydrochloride 1-water 2 mg/stuk samenstelling overeenkomend met ; lidocaÏne 1,6 mg/stuk - zuigtablet - chinolinegeel (e 104) ; glucose, vloeibaar ; honingsmaakstof 503666 a firmenich ; muntolie met verlaagd mentholgehalte ; natuurlijk citroensmaakstof 9722 ; saccharoide natrium x-water (e 954) ; saccharose ; wijnsteenzuur, (l (+) vorm) (e 334) ; zonnegeel fcf (e 110), - various

Holandia - niderlandzki - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

omega pharma nederland b.v. kralingseweg 201 3062 ce rotterdam - ascorbinezuur (l-) (e 300) 30 mg/stuk ; paracetamol 500 mg/stuk - poeder voor drank - butylhydroxyanisol (e 320) ; citroensmaakstof ; citroenzuur 0-water (e 330) ; curcumine (e 100) ; glucose 0-water ; maltodextrine ; maÏszetmeel ; natriumascorbaat (e 301) ; natriumcyclamaat (e 952) ; saccharoide natrium x-water (e 954) ; saccharose ; siliciumdioxide (e 551) ; trinatriumcitraat 2-water (e 331), butylhydroxyanisol (e 320) ; citroenzuur 0-water (e 330) ; curcumin (e 100) (ri) ; lemon flavour ; maltodextrine ; maÏszetmeel ; natriumascorbaat (e 301) ; natriumcyclamaat (e 952) ; saccharoide natrium x-water (e 954) ; saccharose ; siliciumdioxide (e 551) ; trinatriumcitraat 2-water (e 331), - paracetamol, combinations excl. psycholeptics

Holandia - niderlandzki - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

omega pharma nederland b.v. kralingseweg 201 3062 ce rotterdam - xylometazolinehydrochloride 1 mg/ml samenstelling overeenkomend met ; xylometazoline 0,869 mg/ml - neusspray, oplossing - kaliumdiwaterstoffosfaat 0-water (e 340) ; water, gezuiverd ; zeewater, gezuiverd, - xylometazoline

Holandia - niderlandzki - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

omega pharma nederland b.v. kralingseweg 201 3062 ce rotterdam - xylometazolinehydrochloride 0,5 mg/ml samenstelling overeenkomend met ; xylometazoline 0,435 mg/ml - neusspray, oplossing - kaliumdiwaterstoffosfaat 0-water (e 340) ; water, gezuiverd ; zeewater, gezuiverd, - xylometazoline

Unia Europejska - niderlandzki - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochloride - colorectale neoplasma's - antineoplastische middelen - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Unia Europejska - niderlandzki - EMA (European Medicines Agency)

amgen europe b.v. - panitumumab - colorectale neoplasma's - antineoplastische middelen - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. in de tweede lijn in combinatie met folfiri voor patiënten die hebben ontvangen de eerste lijn fluoropyrimidine-gebaseerde chemotherapie (met uitzondering van irinotecan). als monotherapie na de mislukking van fluoropyrimidine-, oxaliplatine en irinotecan-bevattende chemotherapie.

Unia Europejska - niderlandzki - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastische middelen - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Unia Europejska - niderlandzki - EMA (European Medicines Agency)

alfasigma s.p.a. - methylthioniniumchloride - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Unia Europejska - niderlandzki - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - colorectale neoplasma's - antineoplastic agents, protein kinase inhibitors - stivarga is geïndiceerd als monotherapie voor de behandeling van volwassen patiënten met:gemetastaseerde colorectale kanker (crc) die al eerder zijn behandeld met of worden niet beschouwd als kandidaten voor, therapieën - deze omvatten fluoropyrimidine-gebaseerde chemotherapie, een anti-vegf therapie en een anti-egfr-therapie;inoperabele of gemetastaseerde gastro-intestinale stromale tumoren (gist) die gevorderd op of intolerant zijn voor een voorafgaande behandeling met imatinib en sunitinib;hepatocellulair carcinoom (hcc) die eerder werden behandeld met sorafenib.

Unia Europejska - niderlandzki - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - colorectale neoplasma's - antineoplastische middelen - behandeling van gemetastaseerde colorectale kanker (mcrc).